Work

Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.8010

Authors: Alexander I. Spira, Keunchil Park, Julien Mazières, Johan F. Vansteenkiste, Achim Rittmeyer, Marcus Ballinger, Daniel Waterkamp, Marcin Kowanetz, Ahmad Mokatrin, Louis Fehrenbacher

Institutions: Virginia Cancer Specialists, Samsung Medical Center, Sungkyunkwan University, Hôpital Larrey, KU Leuven, Lungenklinik Hemer, Genentech, F. Hoffmann-La Roche AG, NRG Oncology, Kaiser Permanente Northern California

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2408417528

Cites:

Cited by: 121

Related to: 10